Compare BlackBerry Limited (BB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackBerry Limited vs Vertex Pharmaceuticals Incorporated — how do they compare? BlackBerry Limited trades at $11.08 (market cap $6.26B), while Vertex Pharmaceuticals Incorporated trades at $477.46 (market cap $121.89B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 19.5× BlackBerry Limited's market cap, and BlackBerry Limited is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| BB | VRTX | |
|---|---|---|
Market Cap | $6.26B | $121.89B |
Sector | Technology | Health |
52-Week High | $12.81 | $529.59 |
52-Week Low | $3.15 | $366.54 |
Enterprise Value | $6.13B | $116.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $10.71, down 2.37% today, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q1 2026 earnings beat expectations with EPS of $0.06 versus $0.05 expected, driven by QNX software growth. Revenue for 2025 was $534.90M with a net loss of $79M, but 2026 projects a return to profitability. Positive news highlights QNX expansion into robotics and industrial automation.
Outlook is cautiously optimistic as the company's turnaround gains traction, but high valuation ratios (P/E 107.1) and mixed analyst sentiment (14% buy, 86% hold) suggest execution risks remain. Key opportunities include QNX's market penetration, while risks involve competitive pressures and achieving sustained profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
